文献速递其他结缔组织病

2017年EULAR/ACR特发性炎症性肌病分类标准在抗MDA5抗体阳性间质性肺病患者中的外部验证:中国多中心回顾性队列研究

External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China.
PubMed 文献 · Semin Arthritis Rheum · 2025-02-27

该研究在中国四家医院纳入250例抗MDA5抗体阳性IIM相关间质性肺病患者,评估2017年EULAR/ACR分类标准的性能,并与Bohan/Peter联合Sontheimer的CADM标准比较。结果显示70%患者符合EULAR/ACR标准,30%不符合但符合IPAF标准;将抗Jo-1抗体替换为抗MDA5抗体后敏感性升至99.2%,Casal-Domingez标准敏感性为100%。

要点

  • 250例抗MDA5+IIM-ILD患者中,70%符合2017年EULAR/ACR标准,25.7%符合Bohan/Peter标准。
  • 30%未符合EULAR/ACR标准的患者符合IPAF标准,其临床特征和预后与符合者无显著差异。
  • 将抗Jo-1抗体替换为抗MDA5抗体后,EULAR/ACR标准敏感性升至99.2%;Casal-Domingez标准敏感性为100%。

核心结论

  • 约30%临床诊断的抗MDA5抗体阳性IIM-ILD患者无法按2017年EULAR/ACR标准分类,提示此类患者应按IIM-ILD患者管理。
  • 作者建议修改现有标准,将抗MDA5抗体等其他肌炎特异性抗体纳入评分标准。
  • 作者认为未来IIM指南应考虑将间质性肺病纳入诊断标准。

研究设计与样本

  • 中国四家医院的多中心回顾性队列研究,纳入250例成年抗MDA5抗体阳性IIM相关间质性肺病患者。
  • 通过电子病历收集疾病表现、实验室检查和影像学资料。
  • 比较2017年EULAR/ACR标准与Bohan/Peter标准联合Sontheimer的CADM标准的性能和一致性。
  • 评估将抗MDA5抗体纳入EULAR/ACR标准以及Casal-Domingez基于肌炎特异性抗体(MSAs)提出的标准的性能。
  • 比较符合与不符合EULAR/ACR标准的MDA5+IIM-ILD患者的临床特征和预后。

主要发现

  • 250例患者中皮肌炎(DM)占23.6%,临床无肌病性皮肌炎(CADM)占76.4%。
  • 175例(70%)符合EULAR/ACR标准,64例(25.7%)符合Bohan/Peter标准。
  • 根据Sontheimer的CADM标准,60.4%的患者可按Bohan和Peter标准分类。
  • 30%的抗MDA5抗体阳性患者不符合EULAR/ACR标准但符合IPAF标准。
  • 将抗Jo-1抗体替换为抗MDA5抗体后,EULAR/ACR标准敏感性升至99.2%;Casal-Domingez标准敏感性为100%。

关键数值与推荐

  • 2017年EULAR/ACR分类标准在抗MDA5+IIM-ILD队列中敏感性为70%(175/250)。
  • Bohan/Peter标准联合Sontheimer的CADM标准敏感性为25.7%(64/250)。
  • 将抗Jo-1抗体替换为抗MDA5抗体后,EULAR/ACR标准敏感性为99.2%。
  • Casal-Domingez基于MSAs的标准敏感性为100%。
  • 30%的抗MDA5抗体阳性患者不符合EULAR/ACR标准但符合IPAF标准。

临床怎么用

  • 作者认为约30%临床诊断的抗MDA5抗体阳性IIM-ILD患者无法按EULAR/ACR标准分类,此类患者应按IIM-ILD患者管理。
  • 作者建议修改现有标准,将抗MDA5抗体等其他MSAs作为评分标准之一。
  • 作者认为未来IIM指南应考虑将ILD纳入诊断标准。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: The aim of this study was to assess the 2017 EULAR/ACR classification criteria performance for determining idiopathic inflammatory myopathies (IIMs) in a cohort of patients with anti-MDA5 antibody-positive IIM-related interstitial lung disease (anti-MDA5+IIM-ILD). The outcomes of patients, who did not meet the EULAR/ACR criteria, and who had interstitial pneumonia and exhibited an autoimmune phenotype associated with anti-MDA5 positivity were also investigated. METHODS: This retrospective study recruited adult patients from four hospitals in China who were diagnosed with anti-MDA5 antibody-positive IIM-related interstitial lung disease. Data on disease manifestations, laboratory findings, and imaging findings were collected through electronic medical records. The performance and consistency of the 2017 EULAR/ACR classification criteria were compared with those of the Bohan/Peter criteria combined with Sontheimer's CADM criteria. Additionally, this study evaluated the performance of incorporating anti-MDA5 antibodies into the EULAR/ACR criteria and explored the criteria proposed by Casal-Domingez based on myositis-specific antibodies (MSAs). Finally, clinical characteristics and prognoses were compared between patients with MDA5+IIM-ILD who met the EULAR/ACR criteria and those who did not meet the EULAR/ACR criteria. RESULTS: A total of 250 patients with anti-MDA5-related IIM-ILD, including those with dermatomyositis (DM, 23.6 %) and clinically amyopathic dermatomyositis (CADM, 76.4 %), were recruited. Of these, 175 (70 %) and 64 (25.7 %) patients met the EULAR/ACR and Bohan/Peter criteria, respectively. According to Sontheimer's CADM criteria, 60.4 % of patients could be classified according to the Bohan and Peter criteria. Thirty percent of the anti-MDA5 antibody-positive patients did not meet the EULAR/ACR criteria but met the IPAF criteria. The sensitivity of the EULAR/ACR criteria increased to 99.2 % when anti-JO-1 antibodies were replaced with anti-MDA5 antibodies. In this cohort, a sensitivity of 100 % was obtained using the Casal-Domingez criteria. There were no significant differences in clinical characteristics or prognoses between MDA5+IIM-ILD patients who met the EULAR/ACR criteria, those who did not meet the criteria, and those who met the IPAF criteria. CONCLUSION: Approximately 30 % of clinically diagnosed anti-MDA5 antibody-positive IIM-ILD patients cannot be classified according to the EULAR/ACR criteria, suggesting that such patients should be managed as IIM-ILD patients. Modifying the existing criteria by including other MSAs, such as anti-MDA5 antibodies, as one of the scoring criteria is recommended. Future IIM guidelines should consider incorporating ILD into the diagnostic criteria.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Chen B, Xi B, Xin H, et al. External validation of the 2017 EULAR/ACR classification criteria for idiopathic inflammatory myopathies in anti-MDA5 antibody-positive interstitial lung disease patients: A multicenter retrospective cohort study in China. Semin Arthritis Rheum. 2025. PMID: 40056481. doi:10.1016/j.semarthrit.2025.152700

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。